Alphamab Oncology Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Alphamab Oncology has been growing earnings at an average annual rate of 23.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 56.6% per year.
Información clave
23.2%
Tasa de crecimiento de los beneficios
34.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | 56.6% |
| Rentabilidad financiera | -13.2% |
| Margen neto | -84.3% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Alphamab Oncology. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 256 | -216 | 81 | 407 |
| 31 Mar 24 | 237 | -213 | 80 | 407 |
| 31 Dec 23 | 219 | -211 | 80 | 407 |
| 30 Sep 23 | 234 | -214 | 78 | 427 |
| 30 Jun 23 | 250 | -218 | 76 | 446 |
| 31 Mar 23 | 208 | -272 | 82 | 457 |
| 31 Dec 22 | 167 | -326 | 87 | 468 |
| 30 Sep 22 | 183 | -309 | 85 | 467 |
| 30 Jun 22 | 200 | -292 | 83 | 466 |
| 31 Mar 22 | 173 | -352 | 80 | 473 |
| 31 Dec 21 | 146 | -412 | 78 | 481 |
| 30 Sep 21 | 73 | -502 | 77 | 455 |
| 30 Jun 21 | 0 | -592 | 76 | 429 |
| 31 Mar 21 | 0 | -510 | 77 | 380 |
| 31 Dec 20 | 0 | -428 | 78 | 331 |
| 30 Sep 20 | 1 | -652 | 106 | 288 |
| 30 Jun 20 | 2 | -877 | 134 | 245 |
| 31 Mar 20 | -1 | -851 | 132 | 208 |
| 31 Dec 19 | 5 | -833 | 118 | 167 |
| 30 Sep 19 | 3 | -495 | 80 | 131 |
| 30 Jun 19 | 1 | -157 | 41 | 95 |
| 31 Mar 19 | 6 | -176 | 29 | 80 |
| 31 Dec 18 | -1 | -150 | 26 | 66 |
| 31 Dec 17 | 1 | -33 | 13 | 53 |
Ingresos de calidad: 9966 is currently unprofitable.
Margen de beneficios creciente: 9966 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 9966 is unprofitable, but has reduced losses over the past 5 years at a rate of 23.2% per year.
Acelerando crecimiento: Unable to compare 9966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 9966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rentabilidad financiera
Alta ROE: 9966 has a negative Return on Equity (-13.24%), as it is currently unprofitable.